SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Robert K. who wrote (8582)2/1/1999 10:41:00 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Bob, can't tell if you read the previous post. Murphy is saying this about someone. But just about no one cares what he is saying because he has said the same thing over and over. Bluegreens was just using his imagination on how this would play out if the company were XOMA and the exact same words were used in the N.Y. Times.



To: Robert K. who wrote (8582)2/1/1999 10:52:00 PM
From: Bluegreen  Respond to of 17367
 
That's right Bob, I keep forgetting Meningo. is a niche market!LOL And before I stop laughing, will the HMOs cover cost of Neuprex?LOL, LOL,and another LOL! Dang, now I have the hiccups!



To: Robert K. who wrote (8582)2/2/1999 12:58:00 PM
From: aknahow  Respond to of 17367
 
Bob, sometimes things that are obvious get overlooked. Need your opinion. Could Neuprex or BPI be used to treat shock? I am thinking just of the reperfusion results supposedly noticed in subjects receiving Neuprex.

google.com